ENDRA Life Sciences Inc. (NASDAQ:NDRA) Sees Significant Growth in Short Interest

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 232,800 shares, agrowthof1,373.4% from the June 30th total of 15,800 shares. Approximately30.9% of the shares of the company are sold short. Based on an average trading volume of 1,640,000 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 1,640,000 shares, the short-interest ratio is currently 0.1 days. Approximately30.9% of the shares of the company are sold short.

ENDRA Life Sciences Trading Down 8.3%

NASDAQ NDRA opened at $4.84 on Monday. The business’s 50-day moving average price is $4.75 and its 200 day moving average price is $4.53. ENDRA Life Sciences has a twelve month low of $2.90 and a twelve month high of $143.50. The company has a market capitalization of $3.63 million, a PE ratio of -0.03 and a beta of -0.18.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Ascendiant Capital Markets lowered their price objective on ENDRA Life Sciences from $75.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, April 21st. Wall Street Zen raised ENDRA Life Sciences to a “hold” rating in a report on Friday, June 6th.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.